Brought to you by 
Cubist buys Illumigen
19 May 2011
Executive Summary
In October, anti-infectives developer Cubist Pharmaceuticals received an exclusive option to acquire privately held Illumigen Biosciences (studies mutations to develop drugs with improved efficacy and fewer side effects than existing treatments) for $4.7mm. It will pay another $1mm to cover costs of an IND-enabling study for Illumigen's lead hepatitis C candidate IB657, and for operating expenses during the option period.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
- Molecular Diversity
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist buys Illumigen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice